Effect of tamsulosin and minirin in treatment of BPH

Comparison of effectivness of tamsulosin with and without minirin on lower urinary tract symptom of BPH in patient suitable for medical therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201205219819N1

Enrollment

354

Registered

2012-06-18

Start date

2009-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia. Hyperplasia of prostate

Interventions

Intervention 1: Tamsulosin 0.4 mg daily for 2 episode of 2 mounths. Intervention 2: Minirin 0.2 mg nightly for 2 mounth.

Treatment - Drugs

Tamsulosin 0.4 mg daily for 2 episode of 2 mounths

Minirin 0.2 mg nightly for 2 mounth

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Inclusion criteria : Filling consent form ; IPSS more than 7 ; Nocturia more than 3 ; Ability of providing time-urinevolume chart Exclusion criteria : Not filling consent form ; Surgical indication ; History of ischemic heart disease ; Use of drugs like anti cholinergic , antisychotic , alpha blocker which can not be discontinued ; Contraindication to use tamsulosin and minirin ; If any side effect of drugs is present ; Cr more than 2 mg/dl ; PVR more than 200 cc

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
International prostatic symptom score. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: International prostatic symptom score Questionaire.;Nocturia. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: IPSS questionaire.;Nocturnal volume. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: urine volume - time chart.;Post voiding residue. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: trans abdominal sonography.;Prostate volume. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: trans abdominal sonography.;Bladder wall thickness. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: trans abdominal sonography.;Peak flow rate. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: uroflowmetry.	—

Measure

Time frame

International prostatic symptom score. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: International prostatic symptom score Questionaire.;Nocturia. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: IPSS questionaire.;Nocturnal volume. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: urine volume - time chart.;Post voiding residue. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: trans abdominal sonography.;Prostate volume. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: trans abdominal sonography.;Bladder wall thickness. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: trans abdominal sonography.;Peak flow rate. Timepoint: Before intervention - 2 mounth after intervention - 4 mounth after intervention. Method of measurement: uroflowmetry.

—

Secondary

Measure	Time frame
Hyponatremia. Timepoint: befor intervention - 2 days and 7 days after study started. Method of measurement: serum Na.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Nowroozi MD.

Tehran University of Medical Science

mrnowroozi@yahoo.com+98 21 6119 2764

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026